Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05093231




Registration number
NCT05093231
Ethics application status
Date submitted
3/06/2021
Date registered
26/10/2021
Date last updated
18/09/2025

Titles & IDs
Public title
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Scientific title
A Phase II Study Combining Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma (PDA) Patients With Mismatch Repair Deficiency or Tumour Mutation Burden > 4 Mutations/Mb
Secondary ID [1] 0 0
PemOla
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pancreatic Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Pancreatic

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Olaparib

Experimental: Pembrolizumab and olaparib - Pembrolizumab will be given as a fixed dose of 200mg standard dose on Day 1 (+/-3 days) of every 3 weeks cycle , administered intravenously as a \~30 minute infusion, as per standard clinical practice.

Olaparib dose is 300mg given orally, twice daily, from Day 1 to Day 21 continuously of each 3-week cycle. Dosing will start on day 1 of each cycle.


Treatment: Drugs: Pembrolizumab
Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.

Treatment: Drugs: Olaparib
Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective Response Rate (ORR)
Timepoint [1] 0 0
Through study completion, an average of 2 years
Secondary outcome [1] 0 0
Incidence of adverse events (Safety and toxicity)
Timepoint [1] 0 0
Through study completion, an average of 2 years
Secondary outcome [2] 0 0
Duration of Response (DOR)
Timepoint [2] 0 0
Through study completion, an average of 2 years
Secondary outcome [3] 0 0
Progression Free Survival (PSF)
Timepoint [3] 0 0
through study completion, a maximum of 2 years
Secondary outcome [4] 0 0
Overall survival (OS)
Timepoint [4] 0 0
through study completion, a maximum of 2 year
Secondary outcome [5] 0 0
European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQC30)
Timepoint [5] 0 0
Every 9 weeks during the first 27 weeks and then every 12 weeks until death or maximum of 2 years
Secondary outcome [6] 0 0
European Organisation for Research and Treatment of Cancer Pancreatic Cancer Quality of Life Questionnaire (EORTC PAN26)
Timepoint [6] 0 0
Every 9 weeks during the first 27 weeks and then every 12 weeks until death or maximum of 2 years

Eligibility
Key inclusion criteria
* Aged = 18 years old
* Written informed consent
* Histologically or cytologically confirmed PDA
* Confirmation that the PDA has TMB >4 mutations/Mb, or dMMR gene mutation, or MSI-H by IHC. TMB status and dMMR can be obtained from either tissue, or blood.
* Radiologically confirmed stage 4 mPDA, with measurable disease
* Received no more than 1 prior systemic therapy regimen for unresectable (stage 3 or 4) PDA is allowed
* Measurable disease which has not been irradiated in prior radiotherapy
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
* Life expectancy >12 weeks from the date of screening assessment
* Adequate bone marrow function:

* Absolute neutrophil count (ANC) =1.5 x 109 /L
* Haemoglobin (Hb) = 90 g/L
* Platelets =100 x 109 /L
* Adequate liver function:

* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =2.5 x upper limit of normal range (ULN), or <5 x ULN in the presence of liver metastases
* Total bilirubin <1.5 x ULN
* Adequate renal function defined as a calculated creatinine clearance by Cockcroft - Gault of =50 mL/min
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients with resectable or locally advanced PDA
* Other invasive malignancies diagnosed within the last 2 years which have not been treated with curative intent
* Prior immune checkpoint inhibitors or PARP inhibitors. This includes any prior therapy with an anti-PD-1, or anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g, CTLA-4, OX 40, CD137)
* Requirement for non-physiological dose of daily oral steroids, or regular use of any other immunosuppressive agents; prednisolone dose of < 10mg (or equivalent steroid dose) is allowed. Use of inhaled or topical steroids is allowed.
* Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality, which in the judgment of the investigator would place the patient at undue risk or interfere with the trial. Examples include, but are not limited to:

* A history of chronic obstructive pulmonary disease, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, cystic fibrosis or bronchiectasis affecting pulmonary function, causing breathlessness at rest
* Uncontrolled ischaemic heart or other cardiovascular event (myocardial infarction, new angina, stroke transient ischaemic attack, or new congestive cardiac failure) within the last 2 months
* Stable but significant cardiovascular disease defined by heart failure (New York Heart Association Functional Classification III or IV) or frequent angina
* Presence of active infection
* Cirrhotic liver disease, known HIV, chronic active or acute hepatitis B, or hepatitis C
* History of severe allergy or hypersensitivity reactions
* Autoimmune disease requiring chronic use of immunosuppressive agents.
* Replacement therapy using physiological doses for adrenal or pituitary insufficiency is allowed.
* Known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.
* Has known brain metastases and/or carcinomatous meningitis
* Has myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.
* Women who are pregnant, or plan to become pregnant or are lactating.
* Women of child-bearing potential and male patients who are unwilling to adhere to the contraception requirement from informed consent until the last dose of the trial treatment and for 120 days after the last dose of trial treatment.
* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication.
* Concomitant use of known potent CYP3A4 inhibitors and inducers. Restrictions relating to concomitant medications are described in section 10.9. Please consider wash-out periods.
* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to screening.
* Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients
* Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-CNS disease.
* Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
* Participant received colony-stimulating factors (e.g., granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM CSF] or recombinant erythropoietin) within 28 days prior to the first dose of study intervention.
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
* Participant has persistent toxicities (>CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia.
* Has had an allogenic tissue/solid organ transplant
* Judgment by the Investigator that the patient should not participate in the trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/02/2025
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2028
Actual
Sample size
Target
20
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United Kingdom
State/province [1] 0 0
Cambridgeshire
Country [2] 0 0
United Kingdom
State/province [2] 0 0
Cardiff
Country [3] 0 0
United Kingdom
State/province [3] 0 0
Coventry
Country [4] 0 0
United Kingdom
State/province [4] 0 0
Glasgow
Country [5] 0 0
United Kingdom
State/province [5] 0 0
Leeds
Country [6] 0 0
United Kingdom
State/province [6] 0 0
London
Country [7] 0 0
United Kingdom
State/province [7] 0 0
Manchester
Country [8] 0 0
United Kingdom
State/province [8] 0 0
Milton Keynes
Country [9] 0 0
United Kingdom
State/province [9] 0 0
Norwich
Country [10] 0 0
United Kingdom
State/province [10] 0 0
Nottingham
Country [11] 0 0
United Kingdom
State/province [11] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Other
Name
Cambridge University Hospitals NHS Foundation Trust
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Institute for Health Research, United Kingdom
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pippa Corrie
Address 0 0
Cambridge University Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Trial Coordinator
Address 0 0
Country 0 0
Phone 0 0
+44 01223348454
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05093231